NPPC and achondroplasia: Besides that, a CNP analog named vosoritide, that has been used as an experimental drug for the treatment of achondroplasia, can be in the future an option to treat children with nonsyndromic short stature, especially those with heterozygous mutations in the NPR2 or in the NPPC genes (21).